Bayer edges higher as weak consumer healthcare revenues temper drug sales
Frankfurt — Operating earnings at Germany’s Bayer, which is buying US seeds company Monsanto, edged 4% higher as weaker-than-expected consumer healthcare revenues tempered gains in prescription drug sales. Bayer’s adjusted earnings before interest, taxes, depreciation and amortisation (Ebitda) for the third quarter came in at ¤2.20bn ($2.60bn), slightly higher than the average forecast by analysts of ¤2.12bn, helped by continued growth in prescriptions for anti-clotting drug Xarelto. Adjusted Ebitda at the consumer health unit, owner of brands such as sunscreen Coppertone and allergy remedy Claritin, fell a weaker-than-expected 16.5% to ¤274m. Bayer, struggling with price pressure from large US drugstore chains and from consumers switching to cheaper rivals, said the US market environment remained challenging. Bayer said it still expected 2017 Ebitda before special items to come in slightly above last year’s level, now excluding plastics maker Covestro, in which it holds a minority ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.